Tiziana’s Intranasal Anti-CD3 Reduces Neuroinflammation and Boosts Hippocampal Neurogenesis
Tiziana’s intranasal anti-CD3 reversed key brain aging markers and improved cognition in preclinical models by dampening microglial activation and reducing inflammatory markers. The therapy also enhanced hippocampal neurogenesis and reduced cellular senescence, supporting its advancement into clinical trials for age-related cognitive disorders.
1. Preclinical Data Summary
In age-related animal models, intranasal anti-CD3 reversed hallmark brain aging features and improved cognition. The treatment dampened microglial activation that drives chronic neuroinflammation and reduced expression of inflammatory markers, while enhancing neurogenesis in the hippocampus and lowering cellular senescence.
2. Mechanism and Immunomodulation
Foralumab’s intranasal delivery stimulates regulatory T cells that modulate microglial behavior to promote brain repair mechanisms. Downregulation of age-related genes and inflammatory pathways suggests a novel non-invasive approach to slow cognitive decline.
3. Ongoing and Planned Trials
Fourteen patients with non-active secondary progressive multiple sclerosis dosed in an expanded access program showed disease stability or improvement within six months. A Phase 2a na-SPMS trial is under way, with studies in MSA, ALS and Alzheimer’s disease plus expanded preclinical research in aging.